# reload+after+2024-01-23 12:40:13.053153
address1§1460 Broadway
city§New York
state§NY
zip§10036
country§United States
phone§646 397 3970
website§https://renalytix.com
industry§Health Information Services
sector§Healthcare
longBusinessSummary§Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. James R. McCullough M.B.A.', 'age': 55, 'title': 'CEO & Executive Director', 'yearBorn': 1968, 'fiscalYear': 2023, 'totalPay': 814462, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas H. McLain CPA, M.B.A', 'age': 64, 'title': 'President', 'yearBorn': 1959, 'fiscalYear': 2023, 'totalPay': 520828, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Oliver James Sterling III', 'title': 'Chief Financial Officer', 'fiscalYear': 2023, 'totalPay': 490158, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Fergus  Fleming', 'age': 56, 'title': 'CTO & Executive Director', 'yearBorn': 1967, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael J. Donovan M.D., Ph.D.', 'age': 69, 'title': 'Chief Medical Officer', 'yearBorn': 1954, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Howard B. Doran Jr.', 'age': 62, 'title': 'Chief Business Officer', 'yearBorn': 1961, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Salim Gulamabbas Hamir F.C.A.', 'title': 'Company Secretary', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.717
priceToSalesTrailing12Months§5.699441
currency§GBp
forwardEps§-0.18
exchange§LSE
quoteType§EQUITY
shortName§RENALYTIX PLC ORD 0.25P
longName§Renalytix Plc
firstTradeDateEpochUtc§1541491200
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§2dd207bc-2c9e-331b-96da-81925cfc67cd
targetHighPrice§3.93
targetLowPrice§0.86
targetMeanPrice§2.03
targetMedianPrice§1.66
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§0.982
grossMargins§0.13965
ebitdaMargins§0.0
trailingPegRatio§None
